Short Interest in Aevi Genomic Medicine, Inc. (GNMX) Declines By 26.0%
Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) was the target of a large decline in short interest during the month of September. As of September 15th, there was short interest totalling 815,238 shares, a decline of 26.0% from the August 31st total of 1,101,312 shares. Approximately 2.9% of the company’s stock are sold short. Based on an average daily trading volume, of 173,425 shares, the days-to-cover ratio is presently 4.7 days.
Aevi Genomic Medicine (GNMX) opened at 1.28 on Tuesday. The stock’s market cap is $47.50 million. The firm’s 50 day moving average price is $1.29 and its 200 day moving average price is $1.42. Aevi Genomic Medicine has a one year low of $0.98 and a one year high of $17.75.
A number of hedge funds and other institutional investors have recently bought and sold shares of GNMX. TIAA CREF Investment Management LLC grew its holdings in Aevi Genomic Medicine by 16.7% during the 1st quarter. TIAA CREF Investment Management LLC now owns 97,719 shares of the biotechnology company’s stock worth $182,000 after acquiring an additional 13,966 shares in the last quarter. Teachers Advisors LLC acquired a new stake in shares of Aevi Genomic Medicine during the 4th quarter valued at approximately $204,000. Birchview Capital LP raised its position in shares of Aevi Genomic Medicine by 88.2% during the 2nd quarter. Birchview Capital LP now owns 128,000 shares of the biotechnology company’s stock valued at $170,000 after acquiring an additional 60,000 shares in the last quarter. Northern Capital Management LLC raised its position in shares of Aevi Genomic Medicine by 317.9% during the 2nd quarter. Northern Capital Management LLC now owns 106,050 shares of the biotechnology company’s stock valued at $141,000 after acquiring an additional 80,675 shares in the last quarter. Finally, LMR Partners LLP acquired a new stake in shares of Aevi Genomic Medicine during the 2nd quarter valued at approximately $149,000. Hedge funds and other institutional investors own 20.82% of the company’s stock.
Several research analysts have recently issued reports on GNMX shares. Needham & Company LLC lowered their target price on shares of Aevi Genomic Medicine from $9.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, August 16th. Jefferies Group LLC reiterated a “hold” rating and set a $1.50 price target on shares of Aevi Genomic Medicine in a research note on Thursday, September 28th.
About Aevi Genomic Medicine
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease.
Receive News & Stock Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related stocks with our FREE daily email newsletter.